信高敏 HBsAg 检测阳性与非 HBV 相关性 HCC 患者的预后不良显著相关

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-10-11 DOI:10.1111/apt.18300
Xiaosong Li, Xiping Shen, Ji Wu
{"title":"信高敏 HBsAg 检测阳性与非 HBV 相关性 HCC 患者的预后不良显著相关","authors":"Xiaosong Li,&nbsp;Xiping Shen,&nbsp;Ji Wu","doi":"10.1111/apt.18300","DOIUrl":null,"url":null,"abstract":"<p>We have read a recent article titled ‘Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC’, with great interest [<span>1</span>]. This study is significant, as it provides insights into the role of high-sensitivity HBs antigen positivity (hHBsAg+) in prognosis evaluation. These findings have important implications for estimating overall survival (OS) among non-HBV-related hepatocellular carcinoma. While recognising the value of this study, we would like to make the following comments.</p><p>First, although the Cox regression model is widely acknowledged for its utility, its use in scenarios with potential competing risks might lead to overestimation. Consequently, for the OS explored in this paper, especially when different variables are potentially interrelated, employing a competing risks model appears more fitting. Traditional analysis techniques might not adequately account for the influence of secondary events on the primary study endpoint. A competing risk model might provide a more comprehensive viewpoint [<span>2</span>].</p><p>Second, the authors' inclusion of important information such as Barcelona Clinic Liver Cancer stage and laboratory tests to adjust for potential covariates is commendable. However, considering other potential confounders such as the presence of prophylactic antiviral treatment, treatment methods, Charlson Comorbidity Index, nutrition condition and family income might further enhance the robustness of these findings [<span>3-5</span>].</p><p>Last, to our knowledge, men are twice as likely as women to develop non-viral liver fibrosis and five times as likely to develop hepatocellular carcinoma [<span>6</span>]. Given significant sex-specific disparities, a separate analysis for the subgroup could offer more nuanced insights.</p><p>This article is a significant step forward in our understanding of the relationship between hHBsAg+ and poor prognosis. A more comprehensive prediction could be an intriguing topic for further investigation.</p><p><b>Xiaosong Li:</b> conceptualization, investigation, methodology, writing – original draft. <b>Xiping Shen:</b> methodology, investigation, writing – original draft. <b>Ji Wu:</b> conceptualization, writing – review and editing, methodology, investigation, supervision.</p><p>The authors have nothing to report.</p><p>The authors declare no conflicts of interest.</p><p>This article is linked to Yasuura et al papers. To view these articles, visit https://doi.org/10.1111/apt.18229 and https://doi.org/10.1111/apt.18340.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"60 11-12","pages":"1645-1646"},"PeriodicalIF":6.6000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18300","citationCount":"0","resultStr":"{\"title\":\"Letter: Positivity of High-Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non-HBV-Related HCC\",\"authors\":\"Xiaosong Li,&nbsp;Xiping Shen,&nbsp;Ji Wu\",\"doi\":\"10.1111/apt.18300\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We have read a recent article titled ‘Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC’, with great interest [<span>1</span>]. This study is significant, as it provides insights into the role of high-sensitivity HBs antigen positivity (hHBsAg+) in prognosis evaluation. These findings have important implications for estimating overall survival (OS) among non-HBV-related hepatocellular carcinoma. While recognising the value of this study, we would like to make the following comments.</p><p>First, although the Cox regression model is widely acknowledged for its utility, its use in scenarios with potential competing risks might lead to overestimation. Consequently, for the OS explored in this paper, especially when different variables are potentially interrelated, employing a competing risks model appears more fitting. Traditional analysis techniques might not adequately account for the influence of secondary events on the primary study endpoint. A competing risk model might provide a more comprehensive viewpoint [<span>2</span>].</p><p>Second, the authors' inclusion of important information such as Barcelona Clinic Liver Cancer stage and laboratory tests to adjust for potential covariates is commendable. However, considering other potential confounders such as the presence of prophylactic antiviral treatment, treatment methods, Charlson Comorbidity Index, nutrition condition and family income might further enhance the robustness of these findings [<span>3-5</span>].</p><p>Last, to our knowledge, men are twice as likely as women to develop non-viral liver fibrosis and five times as likely to develop hepatocellular carcinoma [<span>6</span>]. Given significant sex-specific disparities, a separate analysis for the subgroup could offer more nuanced insights.</p><p>This article is a significant step forward in our understanding of the relationship between hHBsAg+ and poor prognosis. A more comprehensive prediction could be an intriguing topic for further investigation.</p><p><b>Xiaosong Li:</b> conceptualization, investigation, methodology, writing – original draft. <b>Xiping Shen:</b> methodology, investigation, writing – original draft. <b>Ji Wu:</b> conceptualization, writing – review and editing, methodology, investigation, supervision.</p><p>The authors have nothing to report.</p><p>The authors declare no conflicts of interest.</p><p>This article is linked to Yasuura et al papers. To view these articles, visit https://doi.org/10.1111/apt.18229 and https://doi.org/10.1111/apt.18340.</p>\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"60 11-12\",\"pages\":\"1645-1646\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18300\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/apt.18300\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18300","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

点击文章标题阅读更多内容。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Letter: Positivity of High-Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non-HBV-Related HCC

We have read a recent article titled ‘Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC’, with great interest [1]. This study is significant, as it provides insights into the role of high-sensitivity HBs antigen positivity (hHBsAg+) in prognosis evaluation. These findings have important implications for estimating overall survival (OS) among non-HBV-related hepatocellular carcinoma. While recognising the value of this study, we would like to make the following comments.

First, although the Cox regression model is widely acknowledged for its utility, its use in scenarios with potential competing risks might lead to overestimation. Consequently, for the OS explored in this paper, especially when different variables are potentially interrelated, employing a competing risks model appears more fitting. Traditional analysis techniques might not adequately account for the influence of secondary events on the primary study endpoint. A competing risk model might provide a more comprehensive viewpoint [2].

Second, the authors' inclusion of important information such as Barcelona Clinic Liver Cancer stage and laboratory tests to adjust for potential covariates is commendable. However, considering other potential confounders such as the presence of prophylactic antiviral treatment, treatment methods, Charlson Comorbidity Index, nutrition condition and family income might further enhance the robustness of these findings [3-5].

Last, to our knowledge, men are twice as likely as women to develop non-viral liver fibrosis and five times as likely to develop hepatocellular carcinoma [6]. Given significant sex-specific disparities, a separate analysis for the subgroup could offer more nuanced insights.

This article is a significant step forward in our understanding of the relationship between hHBsAg+ and poor prognosis. A more comprehensive prediction could be an intriguing topic for further investigation.

Xiaosong Li: conceptualization, investigation, methodology, writing – original draft. Xiping Shen: methodology, investigation, writing – original draft. Ji Wu: conceptualization, writing – review and editing, methodology, investigation, supervision.

The authors have nothing to report.

The authors declare no conflicts of interest.

This article is linked to Yasuura et al papers. To view these articles, visit https://doi.org/10.1111/apt.18229 and https://doi.org/10.1111/apt.18340.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Editorial: Allostatic Load and Inflammatory Bowel Disease. Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply. Issue Information Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1